SAM #HT942726QE008

Hazardous Drug Sample Analysis Services for Defense Health Agency (Aberdeen Proving Ground, MD)

This opportunity from the Defense Health Agency seeks a contractor to provide hazardous drug sample analysis services for the Defense Centers for Public Health at Aberdeen Proving Ground, Maryland. - Government Buyer: - Defense Health Agency (DHA), Medical R&D Contracting Division 2, Fort Detrick, MD - Supported by Defense Centers for Public Health Aberdeen (DCPH-A) - Products/Services Requested: - Hazardous drug wipe/swab sample analysis for a range of chemotherapy and hazardous drugs (e.g., Methotrexate, 5-Fluorouracil, Doxorubicin Hydrochloride) - Estimated annual analyses: 200 total, with breakdowns by number of drugs per sample (e.g., 17 for 1 drug, 103 for 6 drugs, etc.) - Supply of sampling media upon request - Courier services for sample pickup and delivery within 24 hours - Disposal of unused samples per quality standards - Return of government shipping containers - Quality control program, weekly and monthly reporting, and electronic data deliverables - Unique or Notable Requirements: - Laboratory must use accredited methodologies and comply with USP 800 and TB-MED 515 - Surge capacity for increased sample volume - Liquidated damages for late or deficient reporting - Best value tradeoff source selection (technical capability, past performance, price) - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Place of Performance: - Defense Centers for Public Health, Aberdeen Proving Ground, MD (primary) - Contracting office at Fort Detrick, MD

Description

 As part of the DCPH-A mission, the Lab Sciences (LS) Directorate requires the analysis of wipe/swab samples for the presence of hazardous drugs in support of pharmacies and Military Treatment Facilities (MTFs) within the Department of War (DoW).  This analysis is mandated for the MTFs using Chemotherapy drugs to ensure their cleaning procedures are effective to ensure safety of the MTF staff and to avoid cross-contamination.  The directives that mandate this semi-annual testing requirement are United Stated Pharmacopiea (USP) 800: Handling Hazardous Drugs and Technical Bulletin-Medical (TB-MED) 515: Occupational Health and Indutrial Hygiene Guidance for the Management, Use and Disposal of Hazardous Drugs.  There is no acceptable level of occupational exposure to Hazardous Drugs.  The LS Directorate of the DCPH-A is the only government laboratory to perform this hazardous drugs analysis as required.  While LS does have the analytical capability to perform hazardous drugs analyses, as a sole source for this effort, there is a need to have back-up laboratory capability for instances of instrument down-time or over-capacity situations.

Objectives for this Requirement are as follows:

The Contractor shall perform analysis on wipe/swab samples provided by the Government for Hazardous Drugs contamination.

The Contractor shall perform the sample analysis within the stated turnaround time (TAT) identified in the Outsource Document and identified in the PWS.

The Contractor shall provide Quality wipe/swab analysis for various hazardous drugs as identified in this PWS in accordance with an accredited methodology.

The Contractor shall dispose of unused samples as prescribed by their quality manual/Standing Operating Procedures and return Government shipping containers.

The Contractor shall supply sampling media upon request.

The Contractor shall pay liquidated damages for late or deficient reporting as detailed in Section 5.of the PWS.

QUESTIONS are due by 20 April 2026 by 1pm Eastern Standard Time (EST)

QUOTATIONS are due by 24 April 2026 by 11am EST.

See the Performance Work Statement (PWS) for complete information regarding this effort. 

View original listing